<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Zohar, Yaniv</dc:creator>
  <dc:creator>Wildbaum, Gizi</dc:creator>
  <dc:creator>Novak, Rostislav</dc:creator>
  <dc:creator>Salzman, Andrew L.</dc:creator>
  <dc:creator>Thelen, Marcus</dc:creator>
  <dc:creator>Alon, Ronen</dc:creator>
  <dc:creator>Barsheshet, Yiftah</dc:creator>
  <dc:creator>Karp, Christopher L.</dc:creator>
  <dc:creator>Karin, Nathan</dc:creator>
  <dc:date>2018-03-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">A single G protein–coupled receptor (GPCR) can activate multiple signaling cascades based on  the binding of different ligands. The biological relevance of this feature in immune regulation has  not been evaluated. The chemokine-binding GPCR CXCR3 is preferentially expressed on CD4+  T cells, and canonically binds 3 structurally related chemokines: CXCL9, CXCL10, and CXCL11.  Here we have shown that CXCL10/CXCR3 interactions drive effector Th1 polarization via STAT1,  STAT4, and STAT5 phosphorylation, while CXCL11/CXCR3 binding induces an immunotolerizing  state that is characterized by IL-10hi (Tr1) and IL-4hi (Th2) cells, mediated via p70 kinase/mTOR  in STAT3- and STAT6-dependent pathways. CXCL11 binds CXCR3 with a higher affinity than  CXCL10, suggesting that CXCL11 has the potential to restrain inflammatory autoimmunity. We  generated a CXCL11-Ig fusion molecule and evaluated its use in the EAE model of inflammatory  autoimmune disease. Administration of CXCL11-Ig during the first episode of relapsing EAE in  SJL/J mice not only led to rapid remission, but also prevented subsequent relapse. Using GFP- expressing effector CD4+ T cells, we observed that successful therapy was associated with  reduced accumulation of these cells at the autoimmune site. Finally, we showed that very low  doses of CXCL11 rapidly suppress signs of EAE in C57BL/6 mice lacking functional CXCL11.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://n2t.net/ark:/12658/srd1318961</dc:identifier>
  <dc:identifier>https://susi.usi.ch/global/documents/318961</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/318961/files/Zohar_JCI_2018.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1172/JCI120358</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1318961</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>The journal of clinical investigation. - 2018, vol. 128, no. 3, p. 1200-1201</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
